# US 8,771,645 B2 · Composition comprising a cell death marker and a wavelength-optimized label > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,771,645 B2 - Document ID: US8771645B2 - Status: Granted - Kind: B2 - Application number: 12/808,012 - Filed: 2008-12-15 - Published: 2010-11-11 - Granted: 2014-07-08 - Earliest claimed: 2007-12-14 - Assignees: UCL Business PLLC - Applicants: Francesca Cordeiro; Stephen Moss; Frederick Fitzke - Inventors: Francesca Cordeiro; Stephen Moss; Frederick Fitzke - Web page: https://patentgrep.com/patent/US8771645B2 ## CPC - A61K 51/087: {the peptide being an annexin, e.g. annexin V} - A61K 49/0004: {Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions} - A61K 49/0032: {Methine dyes, e.g. cyanine dyes} - A61K 49/0041: {Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivo G01N)} - A61K 49/0056: {Peptides, proteins, polyamino acids} - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61P 27/02: Ophthalmic agents - A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention relates to the use of a cell death marker labelled with a wavelength-optimised label for identifying cell death in the eye. Suitable cell death markers are the Annexins and fragments and derivatives thereof. The invention also relates to a pharmaceutical composition comprising a cell death marker labelled with a wavelength-optimised label and a method for monitoring cell death in the eye using a cell death marker labelled with a wavelength-optimised label. ## Claims ### Claim 1 A method for identifying cell death in the eye, comprising providing a composition comprising a cell death marker labeled with a wavelength-optimized label, wherein the cell death marker is an annexin and the wavelength-optimized label is Dy-776 having the structure: or Dy-781 having the structure: ### Claim 2 (depends on 1) The method of claim 1, wherein the cell death marker is annexin 5, 11, 2 or 6. ### Claim 3 (depends on 1) The method of claim 1, wherein the wavelength-optimized label is Dy-776. ### Claim 4 (depends on 1) The method of claim 1, wherein the marker is for identifying retinal cell death. ### Claim 5 (depends on 4) The method of claim 4, wherein the marker is for identifying retinal nerve cell death. ### Claim 6 (depends on 1) The method of claim 1, wherein the marker is for identifying single cell death. ### Claim 7 A method for monitoring cell death in the eye, comprising the steps of: (a) administering a composition comprising a cell death marker labeled with a wavelength-optimized label to a subject, wherein the cell death marker is an annexin and the wavelength-optimized label is Dy-776 having the structure: or Dy-781 having the structure: (b) generating an image of emission wavelength from the subject's eye using an imaging device; wherein the image is a representation of cell death in the eye. ### Claim 8 (depends on 7) The method of claim 7, wherein the cell death marker is an annexin. ### Claim 9 (depends on 8) The method of claim 8, wherein the cell death marker is annexin 5. ### Claim 10 (depends on 8) The method of claim 8, wherein the wavelength-optimised label is Dy-776. ### Claim 11 (depends on 7) The method of claim 7, wherein the marker is for identifying retinal cell death. ### Claim 12 (depends on 11) The method of claim 11, wherein the marker is for identifying retinal nerve cell death. ### Claim 13 (depends on 7) The method of claim 7, wherein the marker is for identifying single cell death. ### Claim 14 (depends on 7) The method of claim 7, wherein the labeled marker is administered systemically, topically or ocularly. ### Claim 15 (depends on 7) The method of claim 7, wherein the step of generating an image is repeated. ### Claim 16 (depends on 15) The method of claim 15, wherein the step of generating and image is repeated to allow real time imaging. ### Claim 17 (depends on 7) The method of claim 7, wherein the method is for diagnosing a degenerative disease of the eye. ### Claim 18 (depends on 17) The method of claim 17, wherein the disease is glaucoma or diabetic retinopathy. ### Claim 19 (depends on 7) The method of claim 7, wherein the disease is a neurodegenerative disease of the brain. ### Claim 20 (depends on 19) The method of claim 19, wherein the disease is Alzheimer's disease. ### Claim 21 A composition comprising a cell death marker labeled with a wavelength-optimized label, wherein the cell death marker is an annexin and the wavelength-optimized label is Dy-776 having the structure: or Dy-781 having the structure: ### Claim 22 (depends on 21) The composition of claim 21, wherein the composition is in a form suitable for intravenous, ocular or topical administration. ### Claim 23 (depends on 21) The composition of claim 21, wherein the cell death marker is annexin 5, 11, 2 or 6. ### Claim 24 (depends on 21) The composition of claim 21, wherein the wavelength-optimized label is Dy-776.